Bron A J, Benjamin L, Snibson G R
Nuffield Laboratory of Ophthalmology, Oxford.
Eye (Lond). 1991;5 ( Pt 4):395-411. doi: 10.1038/eye.1991.65.
In recent years attention has been paid to meibomian gland dysfunction (MGD) as a distinct clinical entity responsible for chronic symptoms and signs and occurring independently or in association with atopy, cicatrising mucosal disorders and rosacea. Attempts to correlate MGD with microbiological and lipid biochemical changes are confounded by the absence of a clear descriptive language for the disorder and its associated changes. Such a language is crucial for the conduct of cross-sectional and natural history studies and therapeutic clinical trials. We present a comprehensive classification and grading scheme of meibomian gland disease, supporting our observations with illustrations.
近年来，睑板腺功能障碍（MGD）作为一种独特的临床实体受到关注，它可导致慢性症状和体征，可独立发生或与特应性、瘢痕性黏膜疾病及酒渣鼻相关。由于缺乏对该疾病及其相关变化的清晰描述性语言，将MGD与微生物学和脂质生化变化相关联的尝试受到了阻碍。这样一种语言对于横断面研究、自然史研究及治疗性临床试验的开展至关重要。我们提出了一种睑板腺疾病的综合分类和分级方案，并辅以图示说明我们的观察结果。
